Dermatologist Kees Tensen (LUMC) will use a KWF grant of 230,000 euros to investigate whether new therapeutic antibodies can be an alternative to brentuximab vedotine in CD30-positive cutaneous T-cell lymphoma (CTCL).
The current treatment of CD30+ CTCL consists of brentuximab vedotine (BV). The antibody targets the CD30 molecule these patients have on their cancer cells. After binding of the antibody to the cancer cell, the toxin ensures that it is cleared.
The dose in which BV is used is limited due to serious side effects. This is most likely because the toxin not only affects cancer cells, but also has an effect on healthy cells. To overcome this disadvantage, a new agent targeting CD30 has recently been developed by the company Tubulis (TUB-010). Experiments show that important disadvantages of BV with TUB-010 are largely negated.
In this project, the researchers want to determine whether TUB-010 is a suitable and better alternative to BV in the treatment of CD30+ CTCL. With the results from the lab and that Tubulis will obtain from clinical trials with Hodgkin lymphoma patients who receive TUB-010, it will be determined whether a clinical trial for CD30+ CTCL patients will be started. The Skin Diseases Department of the LUMC will play a leading role in this.
Bron:
